Pfizer Global Research and Development, 3-9 rue de la Loge 94265 Fresnes, France. patrick.bernardelli@aventis.com
Abstract:
The optimization of 5,8-disubstituted spirocyclohexane-quinazolinones into potent, selective, soluble PDE7 inhibitors with acceptable in vivo pharmacokinetic parameters is presented.